{"id":"NCT00761267","sponsor":"Pfizer","briefTitle":"Study To Assess Pharmacokinetics, Safety & Efficacy of Anidulafungin When Treating Children With Invasive Candidiasis","officialTitle":"A PROSPECTIVE, OPEN-LABEL STUDY TO ASSESS THE PHARMACOKINETICS, SAFETY & EFFICACY OF ANIDULAFUNGIN WHEN USED TO TREAT CHILDREN WITH INVASIVE CANDIDIASIS, INCLUDING CANDIDEMIA","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-02","primaryCompletion":"2018-02","completion":"2018-02","firstPosted":"2008-09-29","resultsPosted":"2018-09-14","lastUpdate":"2019-04-04"},"enrollment":70,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Candidemia"],"interventions":[{"type":"DRUG","name":"Anidulafungin","otherNames":["Eraxis"]},{"type":"DRUG","name":"Fluconazole","otherNames":["Diflucan"]}],"arms":[{"label":"Anidulafungin IV","type":"EXPERIMENTAL"}],"summary":"Prospective, open label study to assess the pharmacokinetics, safety \\& efficacy of anidulafungin when used to treat children (aged 1 month - \\<18 years) with invasive candidiasis, including candidemia (ICC).","primaryOutcome":{"measure":"Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)","timeFrame":"Baseline up to 6 weeks after EOT (up to 91 days)","effectByArm":[{"arm":"Anidulafungin:Participants Aged 1 Month to Less Than(<)2 Years","deltaMin":17,"sd":null},{"arm":"Anidulafungin: Participants Aged 2 to <5 Years","deltaMin":19,"sd":null},{"arm":"Anidulafungin: Participants Aged 5 to <18 Years","deltaMin":30,"sd":null}],"pValues":[]},"eligibility":{"minAge":"1 Month","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":3},"locations":{"siteCount":45,"countries":["United States","Brazil","Canada","Greece","Italy","Russia","South Korea","Spain","Taiwan","United Kingdom"]},"refs":{"pmids":["32032174","30418357"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A8851008&StudyName=Study%20To%20Assess%20The%20Safety%2C%20Pharmacokinetics%2C%20And%20Evaluate%20The%20Response%20To%20Anidulafungin%20When%20Treating%20Children%20With%20Invasive%20Candidiasi"]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":19},"commonTop":["Vomiting","Diarrhoea","Pyrexia","Anaemia","Epistaxis"]}}